Filter Results:
(369)
Show Results For
- All HBS Web
(700)
- Faculty Publications (369)
Show Results For
- All HBS Web
(700)
- Faculty Publications (369)
- February 2018
- Case
Health Savings Accounts: Enabling Consumer Participation
By: Regina E. Herzlinger and James Wallace
Health savings accounts (HSAs), a creation of the 2003 Medicare Modernization Act, had become an integral part of the drive toward consumer-driven health care. Coupled with high-deductible health plans, HSAs allowed consumers to directly control a significant part of... View Details
- August 2017
- Teaching Note
Health Stop (A) and (B)
Teaching Note for HBS Nos. 185-084 and 196-051. View Details
- April 2017
- Teaching Note
CV Ingenuity (A) and (B)
Teaching Note for HBS Nos. 315-045 and 315-087. View Details
- September 2015 (Revised February 2023)
- Case
Emdeon's Acquisition of Change Healthcare: Innovating Transparency Solutions for Health Care Consumers
By: Regina E. Herzlinger, Jeet Guram and Aanchal Raj
Case describes acquisition of Change Healthcare, which provides health care cost and quality information, by Emdeon, a health information exchange, and discusses health care transparency. Emdeon is a billion-dollar company that has grown through acquisitions; at its... View Details
- May 2015
- Case
Acıbadem Healthcare Group
By: Regina E. Herzlinger, Esel Çekin, Natalie Kindred and Gamze Yucaoglu
Acıbadem Healthcare Group is Turkey's only premium nationwide hospital network. This case focuses on Acıbadem’s potential expansion strategy after it was acquired by International Healthcare Holdings Berhad (IHH) in 2011, the world's second-largest publicly listed... View Details
Herzlinger, Regina E., Esel Çekin, Natalie Kindred, and Gamze Yucaoglu. "Acıbadem Healthcare Group." Harvard Business School Case 315-120, May 2015.
- May 2015
- Supplement
OdontoPrev (B)
Herzlinger, Regina E. "OdontoPrev (B)." Harvard Business School Supplement 315-125, May 2015.
- March 2015 (Revised November 2017)
- Case
Bonitas
By: Regina E. Herzlinger and Natalie Kindred
Bonitas, a South African medical scheme (i.e., health insurer), must navigate highly restrictive regulations that make it difficult for Bonitas to innovate, grow, and compete with market leader Discovery as well as providers of alternative insurance products. Bonitas... View Details
Keywords: Health Insurance; Health Care; South Africa; Medical Scheme; Public Policy; Bonitas; Bonitas Medical Fund; National Health Insurance; Health; Health Care and Treatment; Insurance; Policy; Health Industry; Insurance Industry; South Africa; Johannesburg; Africa
Herzlinger, Regina E., and Natalie Kindred. "Bonitas." Harvard Business School Case 315-020, March 2015. (Revised November 2017.)
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- 2015
- Other Teaching and Training Material
Innovating in Healthcare
By: Regina E. Herzlinger, Margo I. Seltzer and Kevin Schulman
With over 71,000 past enrollees, Innovating in Healthcare investigates the issues of health care spending, quality, and access that continue to plague America and global nations alike. With U.S. health care costs trending toward $4 trillion in 2020, the need to... View Details
Herzlinger, Regina E., Margo I. Seltzer, and Kevin Schulman. "Innovating in Healthcare." edX Inc., 2015. Video. (HarvardX Massive Open Online Course.)
- December 2014 (Revised August 2015)
- Case
Improving Melanoma Screening: MELA Sciences
By: Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols
MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and... View Details
- September 2014 (Revised March 2021)
- Case
La Ribera Health Department (A)
By: Regina E. Herzlinger, Emer Moloney and Daniela Beyersdorfer
The La Ribera case studies depict an innovative low cost/high quality privately financed hospital model struggling to achieve alignment with the Six Factors. It is reimbursed by the public sector in a Spanish environment whose Consumers, Structure, and Public Policy... View Details
Keywords: Health Care; Health Care Financing; Health Care Industry; Health Care Operations; Health Care and Treatment; Operations; Business Model; Government and Politics; Programs; Innovation Strategy; Vertical Integration; Health Industry; Europe; Spain
Herzlinger, Regina E., Emer Moloney, and Daniela Beyersdorfer. "La Ribera Health Department (A)." Harvard Business School Case 315-006, September 2014. (Revised March 2021.)
- August 2014
- Case
Blue Cross Blue Shield of Florida, Inc.
By: Regina E. Herzlinger and Meng Li
Keywords: Health; Health Care Industry; Health Insurance; United States; Health Care and Treatment; Health Industry; United States; Florida
Herzlinger, Regina E., and Meng Li. "Blue Cross Blue Shield of Florida, Inc." Harvard Business School Case 315-009, August 2014.
- August 2014 (Revised February 2021)
- Case
Hospital for Special Surgery (A)
By: Regina E. Herzlinger and Stacy Schwartz
Hospital for Special Surgery, a focused factory for orthopedics and joint disease, is contemplating various growth options: further growth in the United Kingdom's National Health Services, management of hospitals in the United States, and/or hospital consulting.... View Details
Keywords: Health Care and Treatment; Nonprofit Organizations; Growth and Development Strategy; Cross-Cultural and Cross-Border Issues; Expansion; Health Industry; United Kingdom; United States
Herzlinger, Regina E., and Stacy Schwartz. "Hospital for Special Surgery (A)." Harvard Business School Case 315-012, August 2014. (Revised February 2021.)
- Article
Shifting toward Defined Contributions—Predicting the Effects
By: Kevin Schulman, Barak D. Richman and Regina E. Herzlinger
Schulman, Kevin, Barak D. Richman, and Regina E. Herzlinger. "Shifting toward Defined Contributions—Predicting the Effects." New England Journal of Medicine 370, no. 26 (June 26, 2014).
- May 2014
- Case
Health Care Accountability: Examples in Cancer Treatment
By: Regina E. Herzlinger and Natalie Kindred
This case is designed to support a discussion of the importance of outcomes evidence in empowering the public to make better health care decisions, the desired level of transparency and accountability for health care providers, and the issues with current measuring and... View Details
Keywords: Accountability; Health Care; Cancer; Cancer Treatment; Memorial Sloan Kettering Cancer Center; Cancer Treatment Centers Of America; Vantage Oncology; Radiology; Risk Adjustment; Treatment Outcomes; Health Care Outcomes; Prostate Cancer; Transparency; Health Care and Treatment; Risk Management; Outcome or Result; Health Industry; United States
- March 2014 (Revised September 2017)
- Case
salaUno: Eliminating Needless Blindness in Mexico
By: Richard Hamermesh, Regina Garcia Cueller and Valeria Moy
In May 2013 the co-founders and co-CEOs of salaUno, Javier Okhuysen and Carlos Orellana, were encouraged by the results of their fledgling start-up. salaUno was founded as a for-profit enterprise in order to have the capital needed for rapid growth and to fulfill its... View Details
Keywords: Medical Services; Developing Countries; Developing Markets; Health Care Industry; Health Services; Healthcare Ventures; Healthcare Startups; Health Care and Treatment; Health; Business Startups; Developing Countries and Economies; Growth and Development Strategy; Health Industry; Mexico; Mexico City
Hamermesh, Richard, Regina Garcia Cueller, and Valeria Moy. "salaUno: Eliminating Needless Blindness in Mexico." Harvard Business School Case 814-041, March 2014. (Revised September 2017.)
- Blog Post
Health Care Transparency: The Fox Is Guarding the Chicken Coop in Washington Again
Now that more people can shop directly for their own health insurance under the Affordable Care Act, they have been transformed from potential patients to consumers, and like any other consumers of goods or services, they want to know if what they're buying is any... View Details
Herzlinger, Regina E. "Health Care Transparency: The Fox Is Guarding the Chicken Coop in Washington Again." Huffington Post, The Blog (March 24, 2014). http://www.huffingtonpost.com/regina-e-herzlinger/health-care-transparency_b_5022531.html.
- March 2014 (Revised September 2014)
- Supplement
Cancer Treatment Centers of America® (B)
By: Regina E. Herzlinger and Natalie Kindred
This case, a follow-up to Cancer Treatment Centers of America (A), HBS No. 313-012, begins with the debate over New Hampshire's certificate-of-need (CON) law, which restricts hospital expansion. This debate ignited significant public criticism of Cancer Treatment... View Details
Keywords: Cancer; Cancer Treatment; Accountability; Outcomes; Outcomes Reporting; Outcomes Measurement; Survival; For-profit Hospitals; Health Care; Healthcare; Hospital; Certificate Of Need; Health Care and Treatment; Outcome or Result; Corporate Accountability; Policy; Health Industry; United States
Herzlinger, Regina E., and Natalie Kindred. "Cancer Treatment Centers of America® (B)." Harvard Business School Supplement 314-003, March 2014. (Revised September 2014.)
- 2014
- Book
Can China Lead? Reaching the Limits of Power and Growth
By: Regina M. Abrami, William C. Kirby and F. Warren McFarlan
At the time of the American Revolution, China was the strongest, richest, and most powerful civilization in the world. The Great Qing Empire ruled China and dominated East Asia by a combination of power and cultural prestige. China's economy was the world's largest.... View Details
Abrami, Regina M., William C. Kirby, and F. Warren McFarlan. Can China Lead? Reaching the Limits of Power and Growth. Harvard Business Review Press, 2014.